Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen) (ProGen)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03328091

Recruitment Status : Completed

First Posted : November 1, 2017

Last Update Posted : January 18, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

University of Texas Southwestern Medical Center

Barbara Ann Karmanos Cancer Institute

Information provided by (Responsible Party):

Huma Rana, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	February 13, 2020
Actual Study Completion Date :	February 13, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Berchuck JE, Boiarsky D, Silver R, Sunkara R, McClure HM, Tsai HK, Siegmund S, Tewari AK, Nowak JA, Lindeman NI, Rana HQ, Choudhury AD, Pomerantz MM, Freedman ML, Van Allen EM, Taplin ME. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022 Aug;6:e2200329. doi: 10.1200/PO.22.00329.

To Top